Sector: Health Care
Director information for ENANTA PHARMACEUTICALS INC
Board as disclosed in the proxy statement filed January 26, 2026. Titles and roles are as stated in that filing and may have changed since.
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Brendan Luu | Chief Business Officer | 51 | [] | [] | 2026 |
| Bruce L.A.Carter, Ph.D. | non-executive Chairman of the Board | 82 | ["Affiliate Professor in the Department of Biochemistry at the University of Washington", "Executive Chairman of Immune Design Corp.", "President and Chief Executive Officer of ZymoGenetics, Inc.", "Chief Scientific Officer of Novo Nordisk", "director of Dr. Reddy\u2019s Laboratories Limited", "director of Mirati Therapeutics"] | [] | 2026 |
| Jay R. Luly, Ph.D. | President, Director and Chief Executive Officer; President and Chief Executive Officer | 69 | ["Entrepreneur in Residence at Oxford Bioscience Partners", "Senior Vice President, Research and Development Operations at Millennium Pharmaceuticals", "Senior Vice President, Drug Discovery and Preclinical Development at LeukoSite, Inc.", "Senior drug discovery positions at Abbott Laboratories"] | [] | 2026 |
| Kristine Peterson | Director | 66 | ["over 30 years of senior executive experience in commercial and business leadership roles in the pharmaceutical and biotechnology industry", "Chief Executive Officer of Valeritas, Inc.", "executive leadership and global marketing roles at Johnson & Johnson", "Senior Vice President, Commercial Operations for Biovail Corporation", "President of Biovail Pharmaceuticals", "20 years at Bristol-Myers Squibb Company in senior sales, marketing and general management roles"] | [] | 2026 |
| Lesley Russell, MBChB, MRCP | Director | 65 | ["Chief Medical Officer of Innocoll Holdings Plc.", "Chief Operating Officer and Chief Medical Officer of TetraLogic Pharmaceuticals", "Executive Vice President and Chief Medical Officer at Cephalon, Inc.", "Senior Vice President and Global Head, Research and Development for Global Branded Products"] | [] | 2026 |
| Mark G. Foletta | Director | 65 | ["Chief Financial Officer and Executive Vice President of Tocagen, Inc.", "Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc.", "Management positions with Intermark, Inc. and Triton Group Ltd.", "Audit Manager with Ernst & Young"] | [] | 2026 |
| Scott T. Rottinghaus, M.D. | Chief Medical Officer | 52 | [] | [] | 2026 |
| Tara L. Kieffer, Ph.D. | Chief Product Strategy Officer | 48 | [] | [] | 2026 |
| Terry C. Vance | Director | 69 | ["Chief Business Officer of BioMotiv, LLC", "Managing Member of EGS Healthcare", "founding partner in Eagle Advisors", "investment banker with Salomon Brothers and Goldman"] | [] | 2026 |
| Yat Sun Or, Ph.D. | Chief Scientific Officer | 74 | [] | [] | 2026 |
| Yujiro S. Hata | Chief Executive Officer; Director | 51 | ["Founder of IDEAYA Biosciences", "Experience as Executive-in-Residence at 5AM Ventures", "Expertise in oncology-focused precision medicine", "executive management", "business and corporate development and M&A experience in several biotechnology companies", "business development roles at Onyx Pharmaceuticals", "Chief Operating Officer at Flexus Biosciences and FLX Bio", "director of Xencor, Inc.", "B.A. in Chemistry from Colorado College", "M.B.A. from Wharton School at the University of Pennsylvania"] | [] | 2026 |
